Sara Pahlavan

Dr. Sara Pahlavan


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2015 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
HFHananeh Fonoudi
Hananeh Fonoudi
HAHassan Ansari
Hassan Ansari
SASaeed Abbasalizadeh
Saeed Abbasalizadeh
MLMehran Rezaei Larijani
Mehran Rezaei Larijani
SKSahar Kiani
Sahar Kiani
HBHossein Baharvand
Hossein Baharvand
Recent advances in the generation of cardiomyocytes (CMs) from human pluripotent stem cells (hPSCs), in conjunction with the promising outcomes from preclinical and clinical studies, have raised new hopes for cardiac cell therapy. We report the development of a scalable, robust, and integrated differentiation platform for large-scale production of hPSC-CM aggregates in a stirred suspension bioreactor as a single-unit operation. Precise modulation of the differentiation process by small molecule activation of WNT signaling, followed by inactivation of transforming growth factor-β and WNT signaling and activation of sonic hedgehog signaling in hPSCs as size-controlled aggregates led to the generation of approximately 100% beating CM spheroids containing virtually pure (∼90%) CMs in 10 days. Moreover, the developed differentiation strategy was universal, as demonstrated by testing multiple hPSC lines (5 human embryonic stem cell and 4 human inducible PSC lines) without cell sorting or selection. The produced hPSC-CMs successfully expressed canonical lineage-specific markers and showed high functionality, as demonstrated by microelectrode array and electrophysiology tests. This robust and universal platform could become a valuable tool for the mass production of functional hPSC-CMs as a prerequisite for realizing their promising potential for therapeutic and industrial applications, including drug discovery and toxicity assays.Significance: Recent advances in the generation of cardiomyocytes (CMs) from human pluripotent stem cells (hPSCs) and the development of novel cell therapy strategies using hPSC-CMs (e.g., cardiac patches) in conjunction with promising preclinical and clinical studies, have raised new hopes for patients with end-stage cardiovascular disease, which remains the leading cause of morbidity and mortality globally. In this study, a simplified, scalable, robust, and integrated differentiation platform was developed to generate clinical grade hPSC-CMs as cell aggregates under chemically defined culture conditions. This approach resulted in approximately 100% beating CM spheroids with virtually pure (∼90%) functional cardiomyocytes in 10 days from multiple hPSC lines. This universal and robust bioprocessing platform can provide sufficient numbers of hPSC-CMs for companies developing regenerative medicine technologies to rescue, replace, and help repair damaged heart tissues and for pharmaceutical companies developing advanced biologics and drugs for regeneration of lost heart tissue using high-throughput technologies. It is believed that this technology can expedite clinical progress in these areas to achieve a meaningful impact on improving clinical outcomes, cost of care, and quality of life for those patients disabled and experiencing heart disease.

1 February 2019 in Biomaterials
Verified
Journal Article
Closed access
FVFahimeh Varzideh
Fahimeh Varzideh
SPSara Pahlavan
Sara Pahlavan
HAHassan Ansari
Hassan Ansari
MHMajid Halvaei
Majid Halvaei
SKSawa Kostin
Sawa Kostin
HBHossein Baharvand
Hossein Baharvand

1 January 2012 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
QTQinghai Tian
Qinghai Tian
SPSara Pahlavan
Sara Pahlavan
KOKatharina Oleinikow
Katharina Oleinikow
JJJennifer Jung
Jennifer Jung
SRSandra Ruppenthal
Sandra Ruppenthal
Lars KaestnerLars Kaestner
Lars Kaestner

8 February 2020 in Journal of Biomedical Materials Research Part A
Verified
Journal Article
Closed access
PDF file
PBPayam Baei
Payam Baei
MHMahya Hosseini
Mahya Hosseini
HBHossein Baharvand
Hossein Baharvand
SPSara Pahlavan
Sara Pahlavan

1 April 2020 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SFSaman Firoozi
Saman Firoozi
SPSara Pahlavan
Sara Pahlavan
MGMohammad-Hossein Ghanian
Mohammad-Hossein Ghanian
SRShahram Rabbani
Shahram Rabbani
MBMaryam Barekat
Maryam Barekat
HBHossein Baharvand
Hossein Baharvand

1 June 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
ABAnne Blaich
Anne Blaich
SPSara Pahlavan
Sara Pahlavan
QTQinghai Tian
Qinghai Tian
MOMartin Oberhofer
Martin Oberhofer
MPMontatip Poomvanicha
Montatip Poomvanicha
FHFranz Hofmann
Franz Hofmann
Cardiac excitation-contraction coupling (EC coupling) links the electrical excitation of the cell membrane to the mechanical contractile machinery of the heart. Calcium channels are major players of EC coupling and are regulated by voltage and Ca2+/calmodulin (CaM). CaM binds to the IQ motif located in the C terminus of the Cav1.2 channel and induces Ca2+-dependent inactivation (CDI) and facilitation (CDF). Mutation of Ile to Glu (Ile1624Glu) in the IQ motif abolished regulation of the channel by CDI and CDF. Here, we addressed the physiological consequences of such a mutation in the heart. Murine hearts expressing the Cav1.2I1624E mutation were generated in adult heterozygous mice through inactivation of the floxed WT Cav1.2L2 allele by tamoxifen-induced cardiac-specific activation of the MerCreMer Cre recombinase. Within 10 days after the first tamoxifen injection these mice developed dilated cardiomyopathy (DCM) accompanied by apoptosis of cardiac myocytes (CM) and fibrosis. In Cav1.2I1624E hearts, the activity of phospho-CaM kinase II and phospho-MAPK was increased. CMs expressed reduced levels of Cav1.2I1624E channel protein and ICa. The Cav1.2I1624E channel showed “CDI” kinetics. Despite a lower sarcoplasmic reticulum Ca2+ content, cellular contractility and global Ca2+ transients remained unchanged because the EC coupling gain was up-regulated by an increased neuroendocrine activity. Treatment of mice with metoprolol and captopril reduced DCM in Cav1.2I1624E hearts at day 10. We conclude that mutation of the IQ motif to IE leads to dilated cardiomyopathy and death.